BRCA2‐associated hereditary tumor syndrome could have an etio‐pathogenetic role in SBA development; thus, we suggest that this syndrome should be considered in patients with an SBA diagnosis below the age of 50 years, especially when a personal or family history of breast cancer is present. This evidence concerns the gene BRCA2 and breast cancer.